Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1990-9-11
|
| pubmed:abstractText |
A multicenter, randomized double-blind clinical trial was conducted among 306 black men and women with mild to moderate hypertension to determine effects of atenolol, captopril, and verapamil SR on measures of quality of life. Patients were randomly assigned to a stable or forced-dose titration sequence. After an 8-week treatment period, the rate of withdrawal from treatment because of adverse effects was low and did not differ by drug treatment group or titration level. Patients taking verapamil SR showed a significantly greater reduction in mean blood pressures than patients treated with atenolol or captopril. Along with absence of worsening on any quality of life total scale scores examined over the treatment period, we found either improvement or no change in the total scale scores for all three treatment groups. Among both male and female patients, comparisons between drug treatment groups showed no differences in degree of change on the total scale scores. In comparisons within each treatment group, improvement in scores of male patients after 8 weeks appeared among those taking atenolol in general well-being and physical symptoms reduction; among male patients taking captopril in general well-being, physical symptoms, and sexual performance; and among male patients receiving verapamil SR in scores in irritability, sleep, and the Digit Span test. Improvement in scores among female patients taking atenolol was found in scores on general well-being, physical symptoms, and sleep; among women taking captopril on general well-being, physical symptoms, and irritability; and among women taking verapamil SR on general well-being. Patients in all treatment groups improved on measures of visuomotor functioning. The research shows that with the three newer generation antihypertensive medications studied, blood pressure control was achieved during the treatment period without negative effects on quality of life scales, along with findings of improvement on some measures. Given the special clinical features of hypertension in black patients, the study underlines as well the potential and utility of systematic tracking of measures of quality of life, while monitoring blood pressures in this patient population.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0003-9926
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
150
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1733-41
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2200384-African Americans,
pubmed-meshheading:2200384-African Continental Ancestry Group,
pubmed-meshheading:2200384-Age Factors,
pubmed-meshheading:2200384-Antihypertensive Agents,
pubmed-meshheading:2200384-Atenolol,
pubmed-meshheading:2200384-Captopril,
pubmed-meshheading:2200384-Double-Blind Method,
pubmed-meshheading:2200384-Drug Administration Schedule,
pubmed-meshheading:2200384-Female,
pubmed-meshheading:2200384-Humans,
pubmed-meshheading:2200384-Hypertension,
pubmed-meshheading:2200384-Male,
pubmed-meshheading:2200384-Middle Aged,
pubmed-meshheading:2200384-Multicenter Studies as Topic,
pubmed-meshheading:2200384-Multivariate Analysis,
pubmed-meshheading:2200384-Quality of Life,
pubmed-meshheading:2200384-Randomized Controlled Trials as Topic,
pubmed-meshheading:2200384-Sex Factors,
pubmed-meshheading:2200384-Verapamil
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group.
|
| pubmed:affiliation |
Department of Behavioral Sciences and Community Health, University of Connecticut Health Center, Farmington 06032.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|